Faron to host webcast on new BEXMAB study data
Faron Pharmaceuticals Oy ("Faron" or the "Company") Faron to host webcast to discuss new data from Phase I/II BEXMAB Study of Bexmarilimab and provide update on the development outlook for next 6-9 months TURKU, FINLAND / BOSTON, MA – October 3, 2023 – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming for effective cancer immunotherapies, today announces it will host a virtual call for investors to provide an update on the most recent Phase I/II BEXMAB data in acute myeloid leukemia (